Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson’s disease
Open Access
- 22 February 2022
- journal article
- research article
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 102, 151-160
Abstract
No abstract availableKeywords
Funding Information
- Science Foundation Ireland
- Irish Research Council
- Maria Curie-Sklodowska University
This publication has 49 references indexed in Scilit:
- RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-concept studyParkinsonism & Related Disorders, 2013
- The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PDNeuropharmacology, 2012
- Isoform-specific histone deacetylase inhibitors: The next step?Cancer Letters, 2009
- Motor Score of the Unified Parkinson Disease Rating Scale as a Good Predictor of Lewy Body–Associated Neuronal Loss in the Substantia NigraArchives of Neurology, 2006
- Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's diseaseJournal of Neuroscience Methods, 2005
- Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl HydroxyamidesJournal of Medicinal Chemistry, 2005
- Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neuronsJournal of Neural Transmission, 2004
- Staging of brain pathology related to sporadic Parkinson’s diseaseNeurobiology of Aging, 2003
- Identification of a Signal-Responsive Nuclear Export Sequence in Class II Histone DeacetylasesMolecular and Cellular Biology, 2001
- AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITYBrain, 1991